Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Journal of Translational Medicine

Volumn 16, Issue 1, 2018, Pages

  Gowen, Michael F ^a   Giles, Keith M ^a   Simpson, Danny ^a   Tchack, Jeremy ^a   Zhou, Hua ^a   Moran, Una ^a   Dawood, Zarmeena ^a   Pavlick, Anna C ^a   Hu, Shaohui ^b   Wilson, Melissa A ^a   Zhong, Hua ^a   Krogsgaard, Michelle ^a   Kirchhoff, Tomas ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CDI Laboratories   (United States)

Author keywords

Antibodies; Biomarker; Immunotherapy; Melanoma; Toxicity

Indexed keywords

AUTOANTIBODY; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; CANCER ANTIBODY;

ACCURACY; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; PHENOTYPE; PREDICTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SUPPORT VECTOR MACHINE; TLR SIGNALING; TNF ALPHA SIGNALING; AGED; BLOOD; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; PROTEOMICS; REPRODUCIBILITY;

AGED; ANTIBODIES, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 85044755708     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-018-1452-4     Document Type: Article

References (36)

1. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43(3):604-11. https://doi.org/10.1016/j.ejso.2016.07.145.
2. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558-68. https://doi.org/10.1016/s1470-2045(16)30366-7.
3. Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 2016;30(6):571-84. https://doi.org/10.1007/s40259016-0204-3.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. https://doi.org/10.1056/NEJMoa1504030.
5. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4(14):272. https://doi.org/10.21037/atm.2016.07.10.
6. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845-55. https://doi.org/10.1056/NEJMoa1611299.
7. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma. N Engl J Med. 2017. https://doi.org/10.1056/NEJMoa1709030.
8. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542-51. https://doi.org/10.1016/s1470-2045(16)30406-5.
9. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternes N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017;8(1):592. https://doi.org/10.1038/s41467-017-00608-2.
10. Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11:75. https://doi.org/10.1186/1479-5876-11-75.
11. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA. 2016;113(42):11919-24. https://doi.org/10.1073/pnas.1611421113.
12. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39. https://doi.org/10.1186/s40425-015-0081-1.
13. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-74. https://doi.org/10.1093/annonc/mdv623.
14. Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27(7):1199-206. https://doi.org/10.1093/annonc/mdw181.
15. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-Induced colitis. Nat Commun. 2016;7:10391. https://doi.org/10.1038/ncomms10391.
16. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and Anti-PD-1. Front Immunol. 2014;5:206. https://doi.org/10.3389/fimmu.2014.00206.
17. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Rese. 2009;1(1):35-43.
18. Jeong JS, Jiang L, Albino E, Marrero J, Rho HS, Hu J, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteom. 2012;11(6):O111-016253. https://doi.org/10.1074/mcp.O111.016253.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
20. Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22(18):4550-5. https://doi.org/10.1158/10780432.ccr-15-2569.
21. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017. https://doi.org/10.1016/j.cell.2017.07.024.
22. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. https://doi.org/10.1126/scitranslmed.3008002.
23. Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39(8):1075-84. https://doi.org/10.1097/pas.0000000000000453.
24. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100(5):1738-41. https://doi.org/10.1210/jc.2014-4560.
25. Segni M, Pucarelli I, Truglia S, Turriziani I, Serafinelli C, Conti F. High prevalence of antinuclear antibodies in children with thyroid autoimmunity. J Immunol Res. 2014;2014:150239. https://doi.org/10.1155/2014/150239.
26. Faustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front Immunol. 2013;4:478. https://doi.org/10.3389/fimmu.2013.00478.
27. Hoyne GF, Elliott H, Mutsaers SE, Prele CM. Idiopathic pulmonary fibrosis and a role for autoimmunity. Immunol Cell Biol. 2017;95(7):577-83. https://doi.org/10.1038/icb.2017.22.
28. Jamilloux Y, Belot A, Magnotti F, Benezech S, Gerfaud-Valentin M, Bourdonnay E, et al. Geoepidemiology and immunologic features of autoinflammatory diseases: a comprehensive review. Clin Rev Allergy Immunol. 2017. https://doi.org/10.1007/s12016-017-8613-8.
29. Chen JQ, Szodoray P, Zeher M. Toll-Like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol. 2016;50(1):1-17. https://doi.org/10.1007/s12016-015-8473-z.
30. Singh VK, Yamaki K, Abe T, Shinohara T. Molecular mimicry between uveitopathogenic site of retinal S-antigen and Escherichia coli protein: induction of experimental autoimmune uveitis and lymphocyte cross-reaction. Cell Immunol. 1989;122(1):262-73.
31. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473-86. https://doi.org/10.1038/nrclinonc.2016.58.
32. Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine. 2008;26(Suppl 8):I9-14.
33. Rendleman J, Vogelsang M, Bapodra A, Adaniel C, Silva I, Moogk D, et al. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. J Med Genet. 2015;52(4):231-9. https://doi.org/10.1136/jmedgenet-2014-102832.
34. Vogelsang M, Martinez CN, Rendleman J, Bapodra A, Malecek K, Romanchuk A, et al. The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis. Clin Cancer Res. 2016;22(13):3268-80. https://doi.org/10.1158/1078-0432.ccr-15-2066.
35. Hakenberg OW. Nivolumab for the treatment of bladder cancer. Expert Opin Biol Ther. 2017;17(10):1309-15. https://doi.org/10.1080/14712598.2017.1353076.
36. Kreamer KM. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol. 2014;5(6):418-31.